In this context, the present study evaluated the clinical characteristics and treatment outcomes in patients with EGFR‐mutated NSCLC who received first‐line treatment with afatinib and second‐line therapy with either osimertinib or other regimens by analyzing RWD in South Korea. Here, EGFR is linked to non-small cell lung carcinoma.